Adjusted net income, a non-GAAP financial measure, was $33.2 million, or $0.09 per diluted share for the fiscal third quarter 2026. This compares to an adjusted net loss, a non-GAAP financial measure, ...
BioAtla, Inc. (NASDAQ: BCAB or the "Company"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ...
Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTC: ONFOP) ("Onfolio" or the "Company"), an owner-operator of cash-generative online businesses, announces ...
Full Year 2025 Revenue of $12.2 Million, up 169% from 2024 Revenue of $2.8 Million for Q4 2025, up 116% from Q4 2024 Gross Profit of $2.3 Million for Q4 2025, a 148% increase from Q4 2024; Gross ...
BioAtla, Inc. (NASDAQ: BCAB or the 'Company”), a global clinical-stage biotechnology company focused on the development of ...
9d
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from ...
These misconceptions make investing seem more complicated than it actually is.
Young and the Invested on MSN
5 retirement investment strategies you can implement today [complete with model portfolios]
This article talks about retirement investment strategies.
Introduces PROPEL, ambitious targets designed to reflect continued earnings growth momentum through 2029Announces initial $2.5 billion share buyback ...
(the “Company”) (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the closing of a $14 million private ...
DALLAS, March 19, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (Nasdaq: ASST; SATA) (“Strive” or the “Company”) today announced its financial results for the fourth quarter ended December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results